Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Gonal-f® (follitropin alfa for injection) is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the α- and β-subunits. The α- and β-subunits have 92 and 111 amino acids, respectively, and their primary and tertiary structure are indistinguishable from those of human follicle stimulating hormone. Recombinant FSH production occurs in genetically modified Chinese Hamster Ovary (CHO) cells cultured in bioreactors. Purification by immunochromatography using an antibody specifically binding FSH results in a highly purified preparation with a consistent FSH isoform profile, and a high specific activity. The biological activity of follitropin alfa is determined by measuring the increase in ovary weight in female rats. The in vivo biological activity of follitropin alfa has been calibrated against the first International Standard for Recombinant Human Follicle Stimulation Hormone established in 1995 by the Expert Committee on Biological Standards of the World Health Organization. Gonal-f® contains no luteinizing hormone (LH) activity. Based on available data derived from physico-chemical tests and bioassays, follitropin alfa and follitropin beta, another recombinant follicle stimulating hormone product, are indistinguishable.
Gonal-f® is a sterile, lyophilized powder intended for subcutaneous injection after reconstitution.
Each Gonal-f® Multi-Dose vial is filled with 600 IU (44 mcg) or 1200 IU (87 mcg) follitropin alfa to deliver 450 IU (33 mcg) or 1050 IU (77 mcg) follitropin alfa, respectively, and contains 30 mg sucrose, 1.11 mg dibasic sodium phosphate dihydrate and 0.45 mg monobasic sodium phosphate monohydrate. Ophosphoric acid and/or sodium hydroxide may be used prior to lyophilization for pH adjustment. Multiple Dose vials are reconstituted with Bacteriostatic Water for Injection (0.9% benzyl alcohol), USP.
Under current storage conditions, Gonal-f® may contain up to 10% of oxidized follitropin alfa.
Therapeutic Class: Infertility
Gonal-F is indicated for:
Induction Of Ovulation And Pregnancy In Oligo-Anovulatory Infertile Women For Whomthe Cause Of Infertility Is Functional And Not Due To Primary Ovarian Failure.
Development Of Multiple Follicles In Ovulatory Infertile Women As Part Of An Assisted Reproductive Technology (ART) Cycle.
Induction Of Spermatogenesis In Infertile Men With Azoospermia And Primary Orsecondary Hypogonadotropic Hypogonadism In Whom The Cause Of Infertility Is Notdue To Primary Testicular Failure.
DOSAGE AND ADMINISTRATION
Important Dosage And Administration Information
Only physicians who are experienced in infertility treatment, should treat women with GONAL-F. GONAL-F is a gonadotropins product capable of causing in women, Ovarian Hyperstimulation Syndrome (OHSS) with or without pulmonary or vascular complications [see WARNINGS AND PRECAUTIONS] and multiple births [see WARNINGS AND PRECAUTIONS]. Gonadotropin therapy requires the availability of appropriate monitoring facilities [see WARNINGS AND PRECAUTIONS]. Use the lowest effective dose of GONAL-F.
Give careful attention to the diagnosis of infertility and the selection of candidates for GONAL-F therapy [see Dosing For Ovulation Induction, Dosing For Multiple Follicle Development As Part Of An Assisted Reproductive Technology (ART) Cycle].
Preparation Of GONAL-F And Selection Of Injection Site
- Store lyophilized Multi-Dose vials refrigerated or at room temperature (2°25°C /36°-77°F) and protected from light.
- Prior to administration, visually inspect parenteral drug products for particulate matter and discoloration, whenever solution and container permit.
- Instruct women and men to use the accompanying syringes, calibrated in International Units FSH for administration. The 27-gauge injection syringe (see figure below) has unit dose markings from 37.5 International Units to 600 International Units FSH for use with GONAL-F Multi-Dose. Instruct women and men to take a specific dose of GONAL-F Multi-Dose. Show women and men how to locate the syringe marking that corresponds to the prescribed dose.
- Each GONAL-F Multi-Dose Vial delivers 450 International Units or 1050 International Units of follitropin alfa, respectively
- Multi-Dose 450 International Units Vial:
- Dissolve the contents of one Multi-Dose vial (450 International Units) with 1 mL Bacteriostatic Water for Injection (0.9% benzyl alcohol), USP. Resulting concentration will be 600 International Units/mL. Following reconstitution as directed, product will deliver the equivalent of six 75 International Units doses.
- Multi-Dose 1050 International Units Vial:
- Dissolve the contents of one Multi-Dose vial (1050 International Units) with 2 mL Bacteriostatic Water for Injection (0.9% benzyl alcohol), USP. Resulting concentration will be 600 International Units/mL. Following reconstitution as directed, product will deliver the equivalent of fourteen 75 International Units doses.
- Multi-Dose 450 International Units Vial:
- Discard unused reconstituted solution after 28 days.
- Administer GONAL-F subcutaneously in the abdomen, upper arm, or upper leg as described in Patient Information and Instructions for Use.
Dosing For Ovulation Induction
Prior to initiation of treatment with GONAL-F:
- Perform a complete gynecologic and endocrinologic evaluation
- Exclude primary ovarian failure
- Exclude the possibility of pregnancy
- Demonstrate tubal patency
- Evaluate the fertility status of the male partner
The dosing scheme is stepwise and is individualized for each woman [see Clinical Studies].
- Administer a starting dose of 75 International Units of GONAL-F subcutaneously daily for 14 days in the first cycle of use.
- In subsequent cycles of treatment, determine the starting dose (and dosage adjustments) of GONAL-F based on the woman's history of the ovarian response to GONAL-F.
- If indicated by the ovarian response after the initial 14 days, make an incremental adjustment in dose of up to 37.5 International Units.
- If indicated by the ovarian response, make additional incremental adjustments in the dose, up to 37.5 International Units, every 7 days.
- Continue treatment until follicular growth an*d/or serum estradiol levels indicate an adequate ovarian response.
- Consider the following when planning the woman's individualized dose:
- Use the lowest dose of Gonal-F consistent with the expectation of good results.
- Use appropriate GONAL-F dose adjustment(s) to prevent multiple follicular growth and cycle cancellation.
- The maximum, individualized, daily dose of GONAL-F is 300 International Units per day.
- In general, do not exceed 35 days of treatment, unless an estradiol rise indicates imminent follicular development.
- When pre-ovulatory conditions are reached, administer human chorionic gonadotropin (hCG) to induce final oocyte maturation and ovulation. Human chorionic gonadotropin, hCG, (5,000 USP units) should be given 1 day after the last dose of GONAL-F.
- Encourage the woman and her partner to have intercourse daily, beginning on the day prior to the administration of hCG and until ovulation becomes apparent.
- Withhold hCG in cases where the ovarian monitoring suggests an increased risk of ovarian hyperstimulation syndrome (OHSS) on the last day of GONAL-F therapy for example estradiol greater than 2,000 pg per mL) [see WARNINGS AND PRECAUTIONS].
- Discourage intercourse when the risk for OHSS is increased [see WARNINGS AND PRECAUTIONS].
- Schedule a follow-up visit in the luteal phase.
- Individualize the initial dose administered in subsequent cycles based on the woman’s response in the preceding cycle.
- As in the initial cycle, do not administer doses larger than 300 International Units of FSH per day. Administer 5,000 USP units of hCG 1 day after the last dose of GONAL-F to complete follicular development and induce ovulation.
- Follow the above recommendations to minimize the chance of development of OHSS.
Dosing For Multiple Follicle Development As part Of An Assisted Reproductive Technology (ART) Cycle
Prior to initiation of treatment with GONAL-F:
- Perform a complete gynecologic and endocrinologic evaluation, and diagnose the cause of infertility
- Exclude the possibility of pregnancy
- Evaluate the fertility status of the male partner
The dosing scheme follows a stepwise approach and is individualized for each woman.
- Beginning on cycle day 2 or 3, administersubcutaneously a starting dose of 150 International Units of GONAL-F daily until sufficient follicular development, as determined by ultrasound in combination with measurement of serum estradiol levels, is attained. In most cases, therapy should not exceed ten days.
- In women whose endogenous gonadotropin levels are suppressed, initiate GONAL-F administration at a dose of 225 International Units per day.
- Adjust the dose after 5 days based on the woman's ovarian response, as determined by ultrasound evaluation of follicular growth and serum estradiol levels.
- Do not make additional dosage adjustments more frequently than every 3-5 days or by more than 75-150 International Units at each adjustment.
- Continue treatment until adequate follicular development is evident, and then administer hCG (5,000 to 10,000 USP units) to induce final follicular maturation in preparation for oocyte retrieval.
- Withhold hCG administration in cases where the ovarian monitoring suggests an increased risk of OHSS on the last day of GONAL-F therapy [see WARNINGS AND PRECAUTIONS].
- Do not use doses greater than 450 International Units per day.
Dosing For Induction Of Spermatogenesis In Males With Azoospermia And Primary Or Secondary Hypogonadotropic Hypogonadism
Prior to initiation of treatment with GONAL-F:
- Confirm azoospermia
- Perform a thorough medical and endocrinologic evaluation to exclude other treatable etiologies of azoospermia
- Confirm hypogonadotropic hypogonadism
- Exclude primary testicular failure
- Normalize serum testosterone levels
The dosing scheme follows a stepwise approach and is individualized for each man.
- GONAL-F must be given in conjunction with hCG.
- Prior to concomitant therapy with GONAL-F and hCG, pretreatment with hCG alone (1,000 to 2,250 USP units two to three times per week) is required to normalize serum testosterone levels.
- Treatment with hCG alone should continue until serum testosterone levels reach the normal range, which may take 3 to 6 months. The dose of hCG may also need to be increased during this time to achieve normal serum testosterone levels.
- After serum testosterone levels have normalized, administer GONAL-F 150 International Units subcutaneously three times a week and hCG 1,000 USP units (or the dose required to maintain serum testosterone levels within the normal range) three times a week. The lowest dose of GONAl-F which induces spermatogenesis should be utilized.
- If azoospermia persists, increase the dose of GONAL-F up to a maximum dose of 300 International Units three times per week. Administer GONAL-F for up to 18 months to achieve adequate spermatogenesis.
Do not double the next dose if a woman or a man misses or forgets to take a dose of GONAL-F.
Dosage Forms And Strengths
600 International Units per mL in 450 International Units multiple-dose vial
600 International Units per mL in 1050 International Units multiple-dose vial
GONAL-F Multi-Dose is supplied in a sterile, lyophilized white powder in multiple dose vials filled with 600 International Units or 1200 International Units in order to deliver 450 International Units and 1050 International Units FSH, respectively, after reconstitution with diluent (Bacteriostatic Water for Injection, USP, containing 0.9% benzyl alcohol as a preservative). Each carton contains syringes with mounted 27G x 0.5 inch needle, calibrated in FSH units (IU FSH) which should be used for administration.
The following package presentations are available:
NDC 44087-9030-1 -One vial GONAL-F Multi-Dose 450 International Units, one prefilled syringe of Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol), 1 mL and six syringes calibrated in FSH Units (IU FSH) for injection
NDC 44087-9070-1 -One vial GONAL-F Multi-Dose 1050 International Units, one prefilled syringe of Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol), 2 mL and ten syringes calibrated in FSH Units (IU FSH) for injection.
Storage And Handling
Lyophilized Multi-Dose vials may be stored refrigerated or at room temperature (2°25°C / 36°-77°F). Following reconstitution, the Multi-Dose vial may be stored refrigerated or at room temperature (2°-25°C / 36°-77°F). Protect from light [see DOSAGE AND ADMINISTRATION].
EMD Serono, Inc, Rockland, MA 02370. Revised: Dec 2020
The following serious adverse reactions are discussed elsewhere in the labeling:
- Hypersensitivity Reactions and Anaphylaxis [see WARNINGS AND PRECAUTIONS]
- Ovarian Hyperstimulation Syndrome [see WARNINGS AND PRECAUTIONS]
- Pulmonary and Vascular Complication[see WARNINGS AND PRECAUTIONS]
- Ovarian Torsion [see WARNINGS AND PRECAUTIONS]
- Abnormal Ovarian Enlargement [see WARNINGS AND PRECAUTIONS]
- Multi-fetal Gestation and Birth [see WARNINGS AND PRECAUTIONS]
- Embryofetal Toxicity [see WARNINGS AND PRECAUTIONS]
- Ectopic Pregnancy [see WARNINGS AND PRECAUTIONS]
- Spontaneous Abortion [see WARNINGS AND PRECAUTIONS]
- Ovarian Neoplasms [see WARNINGS AND PRECAUTIONS]
Clinical Study Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
The safety of GONAL-F was examined in four clinical trials that enrolled 691 women [two trials for ovulation induction (454 women) and two trials for ART (237 women)].
Induction of Ovulation
In a randomized, open-labeled, multicenter, active-controlled trial in oligo-anovulatory infertile women, conducted in the U.S., a total of 118 oligo-anovulatory infertile women were randomized to and underwent ovulation induction with GONAL-F versus a comparator urofollitropin. Adverse reactions occurring in at least 5.0% of women receiving GONAL-F are listed in Table 1.
Table 1: Common Adverse Reactions Reported at a Frequency of ≥ 5% in an U.S. Ovulation Induction Trial
|System Organ Class/Adverse Reactions||GONAL-F|
N=118a (288 treatment cyclesb)
|Body as a Whole -General|
|Central and Peripheral Nervous System|
|Abdominal Pain||9 (7.6%)|
|Intermenstrual Bleeding||6 (5.1)|
|Ovarian Hyperstimulation||8 (6.8%)|
|Ovarian Cyst||17 (14.4%)|
|a total number of women treated with GONAL-F|
b up to 3 treatment cycles per woman
c number of women with the adverse reaction
Development of Multiple Follicles as part of an Assisted Reproductive Technology (ART) Cycle
In a randomized, open-labeled, active-comparator trial conducted in the U.S., a total of 56 normal ovulatory infertile women were randomized and received GONAL-F versus a urofollitropin comparator as part of an ART [in vitro fertilization (IVF) or intracytoplasmic sperm injection cycle (ICSI)] cycle. All women received pituitary down-regulation with gonadotropin releasing hormone (GnRH) agonist before stimulation. Adverse Reactions occurring in at least 5.0% of women are listed in Table 2.
Table 2: Common Adverse Reactions Reported at a Frequency of ≥ 5% in an U.S. ART Trial
|System Organ Class/Adverse Reactions||GONAL-F|
|Central and Peripheral Nervous System|
|Abdominal Pain||3 (5.4%)|
|Pelvic Pain||4 (7.1)|
|a total number of women treated with GONAL-F|
b number of women with the adverse reaction
Induction Of Spermatogenesis
The safety of GONAL-F for induction of spermatogenesis in men with primary or secondary hypogonadotropic hypogonadism was examined in 3 open-label, non-randomized, multi-center, multi-national, escalating dose clinical trials (Trials 1, 2 and 3) conducted in in 76 adult men (aged 16 to 48 years) with primary or secondary hypogonadotropic hypogonadism (defined as serum testosterone <100 ng/mL and low or normal FSH and LH) and azoospermia (sperm concentration <0.1x106/mL). Of the 76 men enrolled, 63 received treatment with GONAL-F.
During these trials, there was one serious adverse reaction of gynecomastia requiring surgical excision of breast tissue in a 50 year old man who received 9 months of therapy with Gonal-F. Pathology report showed gynecomastia with no atypia.
There were no discontinuations due to adverse reactions.
Adverse reactions reported in Trials 1, 2 and 3 by ≥2 patients during treatment with Gonal-f are shown in Table 3.
Table 3. Common Adverse Reactions in Men with Azoospermia and Primary orSecondary Hypogonadotropic Hypogonadism Receiving Gonal-F in Trials 1, 2 and 3 for Induction for Spermatogensis
|Injection site pain||7 (11)|
|Libido decreased||2 (3)|
In addition to adverse events reported from clinical trials, the following adverse reactions have been reported during postmarketing use of GONAL-F. Because these reactions were reported voluntarily from a population of uncertain size, the frequency or a causal relationship to GONAL-F cannot be reliably determined.
Body as a Whole -General: Hypersensitivity reactions including anaphylaxis
Respiratory System: Asthma exacerbation
Vascular Disorders: Thromboembolism
No Information Provided
Included as part of the "PRECAUTIONS" Section
Hypersensitivity Reactions And Anaphylaxis
In the postmarketing experience, serious systemic hypersensitivity reactions, including anaphylaxis, have been reported with use of GONAL-F and GONAL-F. Symptoms have included dyspnea, facial edema, pruritis, and urticaria. If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.
Ovarian Hyperstimulation Syndrome (OHSS)
Ovarian Hyperstimulation Syndrome (OHSS) is a medical entity distinct from uncomplicated ovarian enlargement and may progress rapidly to become a serious medical event. OHSS is characterized by a dramatic increase in vascular permeability, which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium. The early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. Abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement [see Multi-Fetal Gestation And Birth], weight gain, dyspnea, and oliguria have been reported with OHSS. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic reactions [see Ovarian Torsion]. Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy, have been reported in association with OHSS.
OHSS occurs after gonadotropin treatment has been discontinued and it can develop rapidly, reaching its maximum about seven to ten days following treatment. Usually, OHSS resolves spontaneously with the onset of menses. If there is evidence that OHSS may be developing prior to hCG administration [see DOSAGE AND ADMINISTRATION], withhold hCG. Cases of OHSS are more common, more severe, and more protracted if pregnancy occurs; therefore, assess women for the development of OHSS for at least two weeks after hCG administration.
If serious OHSS occurs, stop gonadotropins, including GONAL-F and hCG, and consider whether the woman needs to be hospitalized. Treatment is primarily symptomatic and overall consists of bed rest, fluid and electrolyte management, and analgesics (if needed). Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution as described below. The management of OHSS is divided into three phases as follows:
Management is directed at preventing hemoconcentration due to loss of intravascular volume to the third space and minimizing the risk of thromboembolic phenomena and kidney damage. Thoroughly assess daily or more often, based on the clinical need, fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, total proteins with albumin: globulin ratio, coagulation studies, electrocardiogram to monitor for hyperkalemia, and abdominal girth. Treatment, consisting of limited intravenous fluids, electrolytes, human serum albumin, is intended to normalize electrolytes while maintaining an acceptable but somewhat reduced intravascular volume. Full correction of the intravascular volume deficit may lead to an unacceptable increase in the amount of third space fluid accumulation.
After the acute phase is successfully managed as above, excessive fluid accumulation in the third space should be limited by instituting severe potassium, sodium, and fluid restriction.
As third space fluid returns to the intravascular compartment, a fall in hematocrit and increasing urinary output are observed in the absence of any increase in intake. Peripheral and/or pulmonary edema may result if the kidneys are unable to excrete third space fluid as rapidly as it is mobilized. Diuretics may be indicated during the resolution phase, if necessary, to combat pulmonary edema.
Do not remove ascitic, pleural, and pericardial fluid, unless there is the necessity to relieve symptoms such as pulmonary distress or cardiac tamponade.
OHSS increases the risk of injury to the ovary. Avoid pelvic examination or intercourse, as these may cause rupture of an ovarian cyst, which may result in hemoperitoneum.
If bleeding occurs and requires surgical intervention, control the bleeding and retain as much ovarian tissue as possible. A physician experienced in the management of this syndrome, or who is experienced in the management of fluid and electrolyte imbalances should be consulted.
Pulmonary And Vascular Complications
Serious pulmonary conditions (for example, atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins, including GONAL-F. In addition, thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins, including GONAL-F. Intravascular thrombosis and embolism, which may originate in venous or arterial vessels, can result in reduced blood flow to critical organs or the extremities. Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins. Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions. In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death. In women with recognized risk factors, the benefits of ovulation induction and Assisted Reproductive Technology (ART) need to be weighed against the risks. It should be noted that pregnancy also carries an increased risk of thrombosis.
Ovarian torsion has been reported after treatment with gonadotropins, including GONAL-F. This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries. Early diagnosis and immediate detorsion limit damage to the ovary due to reduced blood supply.
Abnormal Ovarian Enlargement
In order to minimize the hazards associated with abnormal ovarian enlargement that may occur with GONAL-F therapy, individualize treatment and use the lowest effective dose [see DOSAGE AND ADMINISTRATION]. Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of ovarian stimulation [see WARNINGS AND PRECAUTIONS].
If the ovaries are abnormally enlarged on the last day of GONAL-F therapy, do not administer hCG in order to reduce the chance of developing Ovarian Hyperstimulation Syndrome (OHSS) [see Ovarian Hyperstimulation Syndrome (OHSS)]. Prohibit intercourse for women with significant ovarian enlargement after ovulation because of the danger of hemoperitoneum resulting from rupture of ovarian cysts [see Ovarian Hyperstimulation Syndrome (OHSS)].
Multi-Fetal Gestation And Birth
Multi-fetal gestation and births have been reported with all gonadotropin therapy, including therapy with GONAL-F.
During clinical trials with GONAL-F, multiple births occurred in 20% of live births in women receiving therapy for ovulation induction and 35.1% of live births in women undergoing ART. Advise the woman and her partner of the potential risk of multi-fetal gestation and birth before beginning therapy with GONAL-F.
The incidence of congenital malformations after some ART [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. There are no indications that the use of gonadotropins during IVF or ICSI is associated with an increased risk of congenital malformations.
Since infertile women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased in women who become pregnant as a result of ART. Advise women who become pregnant following ART and have: abdominal/pelvic pain (particularly on one side); shoulder, neck or rectal pain; and nausea and vomiting to seek immediate medical attention. Confirm the presence of an intrauterine pregnancy early by β-hCG testing and transvaginal ultrasound.
The risk of spontaneous abortion (miscarriage) is increased with gonadotropin products, including GONAL-F. However, causality has not been established. The increased risk may be a factor of the underlying infertility.
There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have had multiple drug therapy for controlled ovarian stimulation, however, a causal relationship has not been established.
In most instances, treatment of women with GONAL-F will result only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the OHSS and multiple gestation.
The clinical confirmation of ovulation is obtained by direct or indirect indices of progesterone production as well as sonographic evidence of ovulation.
Direct or indirect indices of progesterone production:
- Urinary or serum luteinizing hormone (LH) rise
- A rise in basal body temperature
- Increase in serum progesterone
- Menstruation following a shift in basal body temperature
Sonographic evidence of ovulation:
- Collapsed follicle
- Fluid in the cul-de-sac
- Features consistent with corpus luteum formation
- Secretory endometrium
Patient Counseling Information
Advise women and men to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use)
Hypersensitivity Reactions And Anaphylaxis
Advise women and men to discontinue GONAL-F and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur [see WARNINGS AND PRECAUTIONS].
Ovarian Hyperstimulation Syndrome
Inform women regarding the risks of OHSS [see WARNINGS AND PRECAUTIONS] and OHSS-associated conditions including pulmonary and vascular complications [see WARNINGS AND PRECAUTIONS] and ovarian torsion [see WARNINGS AND PRECAUTIONS] with the use of GONAL-F. Advise women to seek medical attention if any of these conditions occur.
Abnormal Ovarian Enlargement
Inform women regarding the hazards associated with abnormal ovarian enlargement that may occur with GONAL-F therapy. If the ovaries are abnormally enlarged on the last day of GONALF therapy, inform women not to administer hCG and to avoid intercourse [see WARNINGS AND PRECAUTIONS].
Multi-Fetal Gestation And Birth
Advise the woman and her partner of the potential risk of multi-fetal gestation and birth before beginning therapy withGONAL-F [see WARNINGS AND PRECAUTIONS].
Inform women that the incidence of congenital malformations (birth defects) after some Assisted Reproductive Technology [(ART) specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception [see WARNINGS AND PRECAUTIONS].
Inform women undergoing ART that the incidence of ectopic pregnancy may be increased with these procedures, particularly for women with tubal abnormalities. Advise women who become pregnant and have: abdominal/pelvic pain (particularly on one side); shoulder, neck or rectal pain; and nausea and vomiting to seek immediate medical attention [see WARNINGS AND PRECAUTIONS].
Inform women that the risk of spontaneous abortion (miscarriage) is increased with gonadotropin products (including GONAL-F). However, causality has not been established. The increased risk may be a factor of the underlying infertility [see WARNINGS AND PRECAUTIONS].
Advise women not to breastfeed because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation with Gonal-F [see Use In Specific Populations].
Dosing And Use Of GONAL-F Multi Dose
Instruct women and men on the correct usage and dosing of GONAL-F [see DOSAGE AND ADMINISTRATION]. Caution against changing the dosage or the schedule of administration unless instructed to do so by a healthcare provider.
Duration And Necessary Monitoring In Patients Undergoing Therapy With GONAL-F
Prior to beginning therapy with GONAL-F, inform women and men about the time commitment and monitoring procedures necessary for treatment [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
Instructions Regarding A Missed Dose
Inform women and men that if they miss or forget to take a dose of GONAL-F, they should not double the next dose and should call their healthcare provider for further dosing instructions.
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of GONAL-F. However, follitropin alfa showed no mutagenic activity in a series of tests performed to evaluate its potential genetic toxicity including, bacterial and mammalian cell mutation tests, a chromosomal aberration test and a micronucleus test.
Impaired fertility has been reported in rats, exposed to pharmacological doses of follitropin alfa (greater than or equal to 40 International Units per kg per day, greater than or equal to 5 times the lowest clinical dose of 75 International Units) for extended periods, through reduced fecundity.
Use In Specific Populations
GONAL-F is not indicated in pregnant women
The incidence of congenital malformations after some Assisted Reproductive Technology, specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)], may be slightly higher than that after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to a higher incidence of multi-fetal gestations after IVF or ICSI. There is no human data that the use of gonadotropins (including GONAL-F alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations.
The risk of spontaneous abortion (miscarriage) is increased in women who have used gonadotropins products (including GONAL-F) to achieve pregnancy.
In animal studies, the continuous administration of recombinant human FSH during pregnancy resulted in a decrease in the number of viable fetuses and difficult and prolonged delivery. No teratogenic effect has been observed.
In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data on a limited number of exposed pregnancies indicate no adverse reactions of gonadotropins on pregnancy, embryonal or fetal development, parturition or postnatal development following controlled ovarian stimulation.
Embryofetal development studies with recombinant human FSH in rats, where dosing occurred during organogenesis, showed a dose dependent increase in difficult and prolonged parturition in dams, and dose dependent increases in resorptions, pre-and post-implantation losses, and stillborn pups at doses representing 5 and 41 times the lowest clinical dose of 75 International Units based on body surface area. Pre-/post-natal development studies with recombinant human FSH in rats, where dosing occurred from mid-gestation through lactation, showed difficult and prolonged parturition in all dams dosed at 41 times the lowest clinical dose of 75 International Units based on body surface area, along with maternal death and stillborn pups associated with the difficult and prolonged parturition. This toxicity was not observed in dams and offspring dosed at a level 5 times the lowest clinical dose of 75 International Units based on body surface area.
There are no data on the presence of GONAL-F in human milk, the effects on the breastfed infant, or the effects on milk production. Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL F.
Females And Males O Reproductive Potential
Because GONAL-F is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F to a woman [see DOSAGE AND ADMINISTRATION].
Safety and effectiveness in pediatric patients have not been established.
Safety and effectiveness of GONAL-F in postmenopausal women have not been established and it is not indicated in this population.
Ovarian hyperstimulation syndrome (OHSS) and multiple gestations have been observed in women with GONAL-F overdosage [see WARNINGS AND PRECAUTIONS].
GONAL-F is contraindicated in women and men who exhibit:
- Prior hypersensitivity to recombinant FSH products or one of their excipients. Reactions have included anaphylaxis [see WARNINGS AND PRECAUTIONS]
- High levels of FSH indicating primary gonadal failure
- The presence of uncontrolled non-gonadal endocrinopathies (for example, thyroid, adrenal, or pituitary disorders)
- Sex hormone dependent tumors of the reproductive tract and accessory organs
- Tumors of pituitary gland or hypothalamus
GONAL-F is also contraindicated in women who exhibit:
- Abnormal uterine bleeding of undetermined origin
- Ovarian cyst or enlargement of undetermined origin
Mechanism Of Action
GONAL-F stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to bring about final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given, following the administration of GONAL-F, when monitoring of the patient indicates that sufficient follicular development is achieved.
GONAL-F stimulates spermatogenesis in men with hypogonadotropic hypogonadism when administered with hCG.
Serum inhibin, estradiol, and total follicular volume responded as a function of time, with pronounced inter-woman variability in healthy volunteer administered GONAL-F. Pharmacodynamic effect lagged behind FSH serum concentration. Serum inhibin levels responded with the least delay and declined rapidly after discontinuation of GONAL-F. Follicular growth was most delayed and continued even after discontinuation of GONAL-F, and after serum FSH levels had declined. Maximum follicular volume correlated better with inhibin and estradiol peak levels than with FSH concentration. Inhibin rise was an early index of follicular development.
FSH serum levels following fixed (during the first five days) and then adjusted doses of GONAL-F were found to be poor predictors of follicular growth rate. High pre-treatment serum FSH levels may predict lower follicular growth rates.
Inhibin levels reached a plateau during the entire administration period and then returned to baseline despite high inter-male variation and the absence of down-regulation in healthy male volunteers administered GONAL-F.
Single dose and state-state pharmacokinetics of follitropin alfa were determined following subcutaneous administration of GONAL-F to healthy, down-regulated female volunteers, healthy adult male volunteers, and pituitary down-regulated women undergoing in vitro fertilization and embryo transfer (IVF/ET). The pharmacokinetic parameters of follitropin alfa following subcutaneous administration of GONAL-F are presented in Table 4.
Table 4: Pharmacokinetic Parameters (mean ± SD) of Follitropin Alfa
|Healthy Female Volunteers||IVF/ET Patients||Healthy Male Volunteers|
|Dose (IU)||Single Dose|
(7 x 150 IU)
(5 x 225 IU),
(7 x 225 IU)
|AUC (IU*hr/L)||176 ± 87||187 ± 61a||-||220 ± 109||186 ± 23a|
|Cmax (IU/L)||3 ± 1||9 ± 3||-||2.5 ± 0.8||8.3 ± 0.9|
|Absolute Bioavailability (%)||66 ± 39||-||-||-|
|Tmax (hr)||16 ± 10||8 ± 6||-||20 ± 14||10.7 ± 6.7|
|Apparent Vd (L)||-||-||10 ± 3||-||-|
|t1/2 terminal (hr)c||24 ± 11||24 ± 8||32||41 ± 14||32 ± 4|
|CL/F (L/hr)d||-||-||0.7 ± 0.2||0.86 ± 0.48||0.90 ± 0.12|
|AUC=area under the concentration-time curve; CL/F=apparent clearance; Cmax=peak serum concentration;|
Tmax=time of Cmax; t1/2=half-life; Vd=volume of distribution
a Steady-state AUC144 hr-168 hr (after the 7th daily subcutaneous dose)
b Follitropin alfa metabolism has not been studied in humans.
c The elimination rate of follitropin alfa following subcutaneous administration is dependent on the absorption rate.
d The apparent clearance was comparable to that in healthy volunteers.
The absorption rate of follitropin alfa lowers as body mass index (BMI) increases.
Drug Interaction Studies
No studies evaluating the drug interaction potential of follitropin alfa has been conducted.
Induction Of Ovulation
The safety and efficacy of GONAL-F were examined in a randomized, open-label, multicenter, active-controlled trial conducted in the U.S in oligo-anovulatory infertile women. Women were randomized to GONAL-F , administered subcutaneously, or a comparator urofollitropin product, administered intramuscularly.
The primary efficacy parameter was the ovulation rate. Two hundred and thirty-two women received treatment for up to three cycles with GONAL-F (118 women ) or urofollitropin (114 women).
Ovulation results for women who received treatment with GONAL-F in at least one cycle are summarized in Table 5.
Table 5: Cumulative Ovulation and Clinical Pregnancy Rates in Induction of Ovulation Trial
|Cumulativea Percent Ovulation||Cumulativea Clinical Pregnancyd Rate|
|a Cumulative rates were determined per woman over cycles 1, 2, and 3|
b Non-inferior to comparator recombinant human FSH based on a two-sided 95% confidence interval, intent-to-treat analysis.
c Secondary efficacy outcomes. The trial was not powered to demonstrate differences in these outcomes.
d Clinical pregnancy was defined as a pregnancy for which a fetal sac (with or without heart activity) was visualized by ultrasound on day 34-36 after hCG administration
For the 44 woman in the GONAL-F group who achieved clinical pregnancy, 22.7 % did not reach a term pregnancy, 63.6% had singleton births and 13.7% had multiple births.
An additional randomized, open-label, multinational, multicenter trial, active-comparator trial was conducted in oligo-anovulatory infertile women who failed to ovulate or conceive following adequate clomiphene citrate therapy. Results for the primary efficacy outcome of cumulative percent ovulation at Cycle 1 were similar to those presented in Table 5 for the U.S. ovulation induction trial.
Development Of Multiple Follicles As part Of An Assisted Reproductive Technology(ART) Cycle
The efficacy of GONAL-F in ART, was evaluated in a randomized,open-label, multicenter, active-controlled trial conducted ith the U.S, in ovulatory, infertile women undergoing stimulation of multiple follicles for In Vitro Fertilization (IVF) and Embryo Transfer (ET). All women received a gonadotrophin releasing hormone (GnRH) agonist for pituitary down-regulation before randomization and administration of GONAL-F (n=56) or a comparator urofollitropin product (n=58). The primary efficacy endpoint was the number of mature pre-ovulatory follicles on the day of hCG administration. The trial was not powered to demonstrate differences in secondary outcomes.
Treatment outcomes for a single IVF cycle with controlled stimulation with GONAL-F are summarized in Table 6.
Table 6: Treatment Outcomes with GONAL-F in an In Vitro Fertilization Trial in OvulatoryWomen
|Mean number of follicles ≥ 14mm diameter on day of hCGa (n=50)||7.2|
|Mean number of oocytes recovered per patientb (n=49)||9.3|
|Mean Serum E2 (pg/mL) on day of hCGb (n=46)||1221|
|Mean treatment duration in days (range)b(n=56)||10.1 (5-15)|
|Clinical pregnancycrate per attemptb (n=56)||20%|
|Clinical pregnancyc rate per embryo transferb (n=47)||23%|
|a Primary efficacy outcome|
b Secondary efficacy outcomes. The trial was not powered to demonstrate differences in these outcomes.
c Clinical pregnancy was defined as a pregnancy for which a fetal sac (with or without heart activity) was visualized by ultrasound on day 34-36 after hCG administration.
For the 11 woman in the GONAL-F group who achieved clinical pregnancy, 36.3% did not reach a term pregnancy, 36.3% had singleton births and 27.3% had multiple births.
An additional randomized, open-label, multinational, multicenter study in ovulatory infertile women was conducted in non-U.S. countries. Women were randomized to receive either GONAL-F by subcutaneous administration (60 women) or urofollitropin by intramuscular administration (63 women) after down-regulation of the pituitary with a GnRH agonist. The primary efficacy parameter was the number of mature pre-ovulatory follicles on the day of hCG administration. Results over a single IVF cycle for the primary efficacy outcome of mature preovulatory follicles on the day of hCG administration were similar to the primary efficacy results presented in Table 6 for the U.S.ART trial.
Induction Of Spermatogenesis In Males
The efficacy of GONAL-F administered concomitantly with human chorionic gonadotropin (hCG) for induction of spermatogenesis in men with hypogonadotropic hypogonadism was established in three open-label, uncontrolled, non-randomized, multi-center, multi-national, escalating dose clinical trials (Trials 1, 2 and 3) conducted in 78 adult men (aged 16 to 48 years) with primary or secondary hypogonadotropic hypogonadism (defined as serum testosterone <100 ng/mL and low or normal FSH and LH) and azoospermia (sperm concentration <0.1x106/mL). Men were required at study entry to have normal serum cortisol and prolactin levels and be euthyroid. Men less than 21 years of age were required to have either confirmed anosmia or documented bone age >15 years to be eligible for study participation. Enrolled men received three to six months of pretreatment with hCG injection to normalize serum testosterone levels, followed by 18 months of treatment with GONAL-F and hCG. Of the 78 men enrolled in the trials, 63 men were treated with GONAL-F and hCG.
Characteristics of the trial populations are shown in Table 7.
Table 7. Trial Population Characteristics in Trials 1, 2 and 3
|Trial 1 N=32||Trial 2 N=10||Trial 3 N=36|
|Median age (range) (years)||26 (16-48)||37 (26-48)||30 (20-44)|
|Race n (%)|
|Caucasian||31 (97)||7 (70)||31 (86)|
|Asian||1 (3)||3 (30)||3 (8)|
|Prior treatment with gonadotropin (FSH) or GnRH* agonist** (%)||0||5 (50)||4 (11)|
|Mean (SD) testis volume (mL)***||2 (1)||5 (3)||4 (1)|
|N(%) with anosmia (i.e. diagnosis of Kallmann’s syndrome)||12 (37)||2 (20)||13 (36)|
|*Gonadotropin releasing hormone (GnRH)|
**prohibited in Trial 1
***Mean testicular volume was required to be <4 mL in Trial 1 and <6 mL in Trial 3. Testicular size was not considered for enrollment into Trial 2.
The primary efficacy measure in all trials was the proportion of men achieving a sperm density ≥ 1.5 x 106/mL during treatment with Gonal-F. Pregnancy (clinical and chemical) in partners of men desiring fertility was a secondary endpoint. Efficacy results in men who received at least one dose of Gonal-F and had at least one follow-up assessment are summarized in Table 8 and Table 9.
Table 8: Proportion of Men Receiving Gonal-F Who Achieved a Sperm Density ≥ 1.5 x 106/mL
|Trial 1 (n=26)||Trial 2 (n=8)||Trial 3 (n=29)|
|Sperm Concentration ≥ 1.5 x 106/mL|
|Yes||12 (46.2%)||5 (62.5%)||20 (80%)|
|No||14 (53.8%)||3 (37.5%)||5 (20%)|
|95% Confidence Interval||(26.6% -66.6%)||(24.5% 91.5%)||(40.7% -82.8%)|
Table 9: Pregnancy Outcome in Partners of Men Desiring Fertility
|Trial 1 (n=7)*||Trial 2 (n=10)*||Trial 3 (n=26)*,|
|Pregnancy||6 (86%)||3 (30%)||5 (19%)|
|Pregnancy not reaching term||1 (14%)||1 (10%)||2 (8%)|
|Single full-term live births||5 (71%)||2 (20%)||3 (11%)|
|*N reflects number of partners desiring pregnancy who had a partner at the time of enrollment, as not all enrolled men sought fertility|
The time to achievement of sperm density ≥1.5 x 106/mL is summarized in Table 10.
Table 10: Time to Achievement of Sperm Density ≥ 1.5 x 106/ mL in Men Receiving Gonal-F
|Trial 1 (n=26)||Trial 2 (n=8)||Trial 3 (n=29)*|
|Number (%) of Men Achieving Sperm Concentration|
|n||12 (46)||5 (62)||22 (76)|
|Time (Months) to Sperm Concentration ≥ 1.5 x 106/mL|
|Range||(2.7 – 18.1)||(8.8 – 11.7)||(2.8 – 18.2)|
(follitropin alfa for injection)
This leaflet contains information about Gonal-f® Multi-Dose. This drug has been prescribed to you by your doctor for treating infertility. To help you prepare and use this medicine, you should read these instructions carefully and ask your doctor, nurse, or pharmacist to explain anything you do not understand. Keep this leaflet. You may want to read it again.
What is Gonal-f® Multi-Dose?
Gonal-f® Multi-Dose is an injectable hormone contained in a stoppered glass vial. The hormone in the vial is in the form of a white powder. The carton containing the vial of drug also contains a syringe labeled 'Bacteriostatic Water for Injection, USP'. This water must be mixed with the white powder in the vial to form a clear liquid solution for injection. Injection syringes for use with Gonal-f® Multi-Dose are also included in the carton. These injection syringes can only be used to administer Gonal-f® Multi- Dose. Gonal-f® Multi-Dose is only available with a prescription.
Gonal-f® Multi-Dose contains follitropin alfa, which is similar to the human hormone 'follicle stimulating hormone'; the abbreviation is 'FSH'. FSH belongs to the group of hormones associated with human reproduction. In women, FSH causes the ovaries to produce eggs. In men, FSH causes sperm production.
The hormone in Gonal-f® Multi-Dose is manufactured to meet standards for quality and purity. It cannot be taken by mouth since the acids in your stomach would destroy the hormone before it was absorbed into the body. Gonal-f® Multi-Dose is given as an injection usually every day in women and three times per week in men. It is prescribed to patients needing hormone replacement or supplementation to produce either eggs or sperm.
The Gonal-f® Multi-Dose 450 IU (33 mcg) vial is filled with 600 IU of drug in order to deliver 450 IU in several smaller daily doses. This provides between 2 and 6 commonly prescribed daily doses.
The Gonal-f® Multi-Dose 1050 IU (77 mcg) vial is filled with 1200 IU of drug in order to deliver 1050 IU in several smaller daily doses. This provides between 3 and 14 commonly prescribed daily doses.
Your doctor or nurse will tell you the number of units (IU FSH) of Gonal-f® to use each day and the number of days to use the same vial. It is common for a small amount of drug to be leftover in each vial that can not be retrieved with a syringe. This is normal. Any drug remaining in the vial after your treatment is complete should be discarded.
Your doctor, nurse, or pharmacist will show you how to inject the prescribed dose. Usual injection sites include the skin on the stomach, upper leg, or upper arm.
The Gonal-f® liquid solution may be stored refrigerated or at room temperature for a maximum of 28 days from the day the powder is mixed with the water. Do Not Freeze. Discard unused liquid solution after 28 days.
Use only the prescribed dose. Call your doctor immediately should you accidentally inject more than the prescribed dose.
What are the uses of Gonal-f® Multi-Dose?
Doctors specializing in infertility or reproductive health prescribe Gonal-f® Multi-Dose to those patients trying to have a child but for a variety of reasons need medical assistance. After a thorough medical exam to determine your specific medical condition, your doctor may prescribe Gonal-f® Multi- Dose because you require hormone replacement or supplementation as part of your treatment program. Gonal-f® Multi-Dose can be used in women seeking pregnancy or in men with a rare condition that affects sperm production. Gonal-f® Multi-Dose may be one of several drugs prescribed to a patient as part of a treatment program.
Do NOT take Gonal-f® Multi-Dose if you have allergies to any of these materials:
- sodium phosphate
- benzyl alcohol
Do NOT take Gonal-f® Multi-Dose if you are pregnant or breast feeding.
Medical conditions you should tell your doctor about.
If you have any of the following conditions, make sure to tell your doctor before starting or continuing use of Gonal-f®:
- Abnormal bleeding from the uterus or vagina in women
- Swollen, enlarged or painful ovaries in women
- Cancer of the sex organs (uterus, ovaries, testes)
- Permanent damage to the male sex organs (testes)
- Uncontrolled thyroid or adrenal problems
- Cancer of the brain
How to Prepare Gonal-f® Multi-Dose for Use
See your doctor, nurse, or pharmacist to obtain training in the preparation and use of Gonal-f® Multi- Dose.
REVIEW THESE STEPS BEFORE YOU PREPARE OR ADMINISTER GONAL-F MULTIDOSE.
Make sure you have all the necessary items listed below before you begin.
- vial containing Gonal-f® Multi-Dose (white powder)
- single pre-filled syringe labeled 'Bacteriostatic Water for Injection, USP'
- 27-gauge injection syringe with unit dose markings from 37.5 IU to 600 IU FSH for use with the Gonalf Multi-Dose.
- alcohol wipes
- hard plastic or metal container (like an empty coffee can) suitable for safe disposal of used syringes and needles.
Step 1: Mixing (reconstituting) the vial containing Gonal-f®® Multi-Dose
- Wash your hands with soap and water.
- Using your thumb, flip off the plastic cap of the Gonal-f® Multi-Dose vial.
- Wipe the top of the vial stopper with an alcohol wipe.
- Carefully twist the needle cap off the syringe labeled 'Bacteriostatic Water for Injection, USP'. Do not touch the needle or allow the needle to touch any surface.
- Do not shake the vial. If bubbles appear, wait a few moments for the bubbles to settle. The liquid drug should be clear.
Position the needle of the syringe of water in a straight, upright position over the marked center circle of the rubber stopper on the vial of Gonal-f® Multi-Dose powder. Keep the needle in a straight, upright position as you insert it through the center circle, or it may be difficult to depress the plunger. Slowly inject the water into the vial by depressing the syringe plunger. The water and white powder will mix to form a clear liquid. When all the water has been injected into the vial, withdraw the needle and safely dispose of it immediately in your needle container. Do not use this needle to inject your dose.
Do not use the Gonal-f® Multi-Dose liquid solution if it contains any particles. Report this to your doctor, nurse, or pharmacist immediately.
Step 2: Determining your dose on the injection syringe
Your doctor will instruct you to take a specific dose of Gonal-f® Multi-Dose. Your doctor, nurse, or pharmacist should show you how to locate the syringe marking that corresponds to your prescribed dose (see illustration below).
If your doctor or nurse instructs you to increase or decrease your dose for 1 or more days, find the correct dose marking on the injection syringe and make the change as directed. Contact your doctor or nurse if you have questions.
Step 3: Preparing your dose
- Wipe the rubber stopper of the vial of Gonal-f® Multi-Dose liquid with an alcohol wipe.
- Carefully pull the cap from the needle. Do not touch the needle or allow the needle to touch any surface. Firmly hold the vial of Gonal-f® Multi-Dose liquid on a flat surface, insert the needle through the marked center circle of the rubber stopper.
- Keeping the needle in the vial, lift the vial and turn it upside down with the needle pointing toward the ceiling. With the needle tip in the liquid, slowly pull back the plunger until the syringe fills to slightly more than the mark for your prescribed dose. Next, keeping the needle in the vial, slowly adjust the plunger to your prescribed dose – this will clear away any air bubbles.
- Check that you have the plunger set at your prescribed dose.
- Remove the syringe needle from the vial. Do not touch the needle or allow the needle to touch any surface.
You should now be ready to prepare to receive the injection.
Step 4: Injecting your dose
Your doctor, nurse, or pharmacist should provide you with injection training. Inject the prescribed dose as directed. Usual injection sites include the skin on the stomach, upper arm, or upper leg. Change the injection location each day to minimize discomfort. Dispose of all used syringes and needles safely in a container.
The injection syringes provided with Gonal-f® Multi-Dose are designed for use only with this product. Do NOT use the injection syringes to administer other drugs or hormones. All unused syringes should be discarded.
Step 5: Storing Your Vial of Gonal-f® Multi-Dose Between Uses
- After each use, the vial containing the Gonal-f® Multi-Dose liquid must be stored away from light and may be stored refrigerated or at room temperature between 36°- 77° F (2°- 25° C) for up to 28 days. Otherwise, the drug's potency can be reduced. Do not store the drug in the syringe.
- If you are traveling, keep the vial stored away from light and extreme temperatures. Do not freeze.
- Allow the liquid solution to adjust to room temperature prior to administering your injection.
- Check that the Gonal-f® liquid solution is clear. Do not use if it contains any particles. Report this to your doctor, nurse or pharmacist immediately.
Are there any side effects associated with the use of Gonal-f® Multi-Dose?
Your doctor or staff member should review with you the risks and benefits of using Gonal-f® Multi- Dose. As with any medication, report any and all side effects, symptoms, or physical changes to your doctor.
The most common side effects are headache, ovarian cysts, upset stomach, and sinus infections in women and skin pimples, breast pain and growth, and tiredness in men. Needle injections may cause some discomfort.
Use of fertility drugs can be associated with fertilization of more than 1 egg. This can lead to complications for the mother and the birth of 2 or more babies. Pregnancy loss (miscarriage) is higher in women receiving fertility drugs than in women not taking fertility drugs.
Gonal-f® is a potent drug which should be used at the lowest dose expected to achieve the desired results. When used in women, your doctor should monitor your response often to avoid overdose which can lead to serious side effects including blood clots.
Contact your doctor if you take more than the prescribed amount of Gonal-f® or experience severe pain or bloating in the stomach or pelvic area, severe upset stomach, vomiting, and weight gain.
In rare cases, ovarian cancer has been reported in women receiving many courses of fertility drugs.
What should you do if you forget to take Gonal-f® Multi-Dose?
Do NOT take a double dose of Gonal-f® . Contact your doctor if you forget to take a dose of Gonal-f® .
Can you take Gonal-f® Multi-Dose with other medicines?
Inform your doctor and pharmacist if you are taking or have taken any other medicines, even those not requiring a prescription.
Where can more information about Gonal-f® Multi-Dose be obtained?
This leaflet is a summary of the important patient information about Gonal-f® Multi-Dose. If you have any questions or problems, talk to your doctor or other health care provider.
Gonal-f® Multi-Dose is manufactured and distributed by EMD Serono, Inc. You can also visit the Web site www.fertilitylifelines.com or contact EMD Serono at 1-866-538-7879.
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors